Did you buy this “Monkey Pox Stock” when I first wrote about it?
when we started Daily Power StockOur mission was simple: find opportunities to profit, regardless of what the market did.
Since April, the market has been anything but stable:
The chart above shows the total daily return of the S&P 500 since April 18, 2022 – the day we launched Daily Power Stock.
The index was in the green for three days before falling as much as 16% in June.
It’s down 5.6% as I write this.
Even so, some of my recent picks look like “maximum momentum” as market volatility continues:
One stock I told you about on July 15th is up 43% since I shared it with you… and it still has a “strong bullish” stock strength rating, so I’m highly convinced that this run is just the beginning.
Monkeypox Power Stock
Just when we thought we were past the madness of infectious diseases, along came monkeypox.
According to the Centers for Disease Control and Prevention, 49 states and the District of Columbia have all reported cases of chickenpox.
It spread so far and fast that the US government and the World Health Organization declared the outbreak a health emergency.
Full of power SIGA Technologies Inc. (Nasdaq: SIGA) predate the outbreak.
SIGA develops drugs to fight infectious diseases in the US. Its lead product, TPOXX, is an antiviral drug that treats smallpox. TPOXX’s use is expanding to treat monkeypox.
The company has partnered with Cipla Therapeutics to develop and manufacture drugs used against various biological threats.
In May, the US Department of Defense awarded SIGA $7.5 million for TPOXX to fight monkeypox.
SIGA Technologies shares receive a “strong bullish” rating 89 out of 100 on our stock strength rating system, and we expect it to beat the broader market 3 times in the next 12 months.
SIGA’s growth potential is one of the reasons I like this stock.
In the first quarter of 2022, SIGA reported total revenues of $10.5 billion – a A 118.8% increase in revenues compared to the corresponding period a year ago!
The quality of the stock is another strong point. SIGA knows how to make money!
The company’s operating margin – the profit on $1 of sales after deducting production costs and wages – is a whopping 62.9%.
the average of his peers in the industry negative 1,213.8%. That’s not a typo, folks!
SIGA presents “Maximum Momentum”
since I told you about SIGA last month, The stock jumped another 43%.!
Over the past 12 months, SIGA 301.3% increasewhile its industry peers decrease by an average of 29.8%.
The S&P 500 is only up 7.2% since I introduced SIGA Daily Power Stock.
This shows the “maximum momentum” we look for in stocks.
If you bought when I told you about SIGA, well done! I would love to hear from you. Write to my team and me Anytime to let us know if you’ve bought Power Shares and how they’re performing!
I have higher conviction and further earnings on the horizon for SIGA.
Because monkeypox is considered a global health emergency, countries are requesting vaccines now.
With SIGA’s varicella vaccine already in the pipeline, its future growth looks promising.
But SIGA is not the last winner we had with her Daily Power Stock:
- Phototronics Inc. (NASDAQ: PLAB) – The manufacturer of key components used in semiconductors 28% increase since I introduced it on July 7th. The stock gets “Strong Bullish” 97 Overall stock strength rating today.
- San Juan Basin Royalty Trust (NYSE: SJT) – This company owns royalties on properties used for oil and natural gas mining. its earn 20% since I told you about it in Mayand his 90 The overall stock strength rating tells us it’s still a smart buy.
This while the broader market continues to struggle after a decline at the beginning of the year.
Be sure to open ours Daily Power Stock Email when it arrives in your inbox every weekday at 7am Eastern for more market crushing stocks.
Stay tuned: Book publishing powerhouse
Remember: we advertise Daily Power Stock Five days a week to give you access to the top companies our proprietary equity power rankings identify!
Stay tuned for the next issue, where I’ll share all the details about a top-rated American multinational publishing, education and media company.
Matt Clark, CMSA®
Research analyst, money and markets
post Scriptum Remember, if you purchased one of the stocks I featured in Daily Stock Power, we’d love to hear how you did… because knowing we’re helping real people make money is why we do what we do here at Money & Markets! Contact Feedback@MoneyandMarkets.com At any time.
Monkeypox Stock: “Strong Bullish” Pharma Co. Source link Monkeypox Stock: “Strong Bullish” Pharma Co.
The post Monkeypox Stock: “Strong Bullish” Pharma Co. appeared first on California News Times.